Huntington National Bank Acquires 4,655 Shares of Thermo Fisher Scientific Inc (TMO)
Huntington National Bank boosted its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 195,348 shares of the medical research company’s stock after purchasing an additional 4,655 shares during the quarter. Huntington National Bank owned about 0.05% of Thermo Fisher Scientific worth $36,959,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Proficio Capital Partners LLC grew its holdings in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares during the period. Cribstone Capital Management LLC grew its holdings in Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after purchasing an additional 50 shares during the period. Shine Investment Advisory Services Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter worth about $113,000. Chicago Partners Investment Group LLC purchased a new stake in Thermo Fisher Scientific in the second quarter worth about $108,000. Finally, Ropes Wealth Advisors LLC grew its holdings in Thermo Fisher Scientific by 15.8% in the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after purchasing an additional 97 shares during the period. Institutional investors and hedge funds own 83.78% of the company’s stock.
In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Seth H. Hoogasian sold 4,140 shares of the stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the completion of the transaction, the vice president now owns 25,518 shares in the company, valued at $4,537,100.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,420 shares of company stock worth $11,308,477. 0.49% of the stock is owned by insiders.
A number of equities research analysts have weighed in on the stock. Jefferies Group LLC restated a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a report on Thursday, September 7th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Morgan Stanley reiterated an “overweight” rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $205.71.
Thermo Fisher Scientific Inc (NYSE:TMO) opened at $190.17 on Friday. The firm has a market cap of $76,030.00, a P/E ratio of 20.78, a P/E/G ratio of 1.73 and a beta of 1.08. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $201.20. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.03 earnings per share. equities analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be given a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.